For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
Scope of the Report:
This report focuses on the Human Coagulation Factor VIII in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.
The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.
Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.
Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.
Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.
The worldwide market for Human Coagulation Factor VIII is expected to grow at a CAGR of roughly 2.8% over the next five years, will reach 8770 million US$ in 2023, from 7440 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Shire (Baxter)
- Hualan Bio
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Recombinant Factor VIII
- Plasma-derived Factor VIII
Market Segment by Applications, can be divided into
- Hemophilia A
- Spontanous / Trauma
There are 15 Chapters to deeply display the global Human Coagulation Factor VIII market.
Chapter 1, to describe Human Coagulation Factor VIII Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Human Coagulation Factor VIII, with sales, revenue, and price of Human Coagulation Factor VIII, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Human Coagulation Factor VIII, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Human Coagulation Factor VIII market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source